Outcome and potentially modifiable risk factors for candidemia in critically ill burns patients: A matched cohort study.


Journal

Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 06 09 2018
revised: 26 10 2018
accepted: 20 11 2018
pubmed: 28 11 2018
medline: 19 3 2019
entrez: 28 11 2018
Statut: ppublish

Résumé

Patients with extensive burns are at risk of developing candidemia. To identify potentially modifiable risk factors and outcomes of candidemia in critically ill burns patients. Retrospective matched cohort study including adult burns patients. Patients who developed candidemia were matched with burns patients with Candida spp colonisation and sepsis or septic shock without candidemia in a ratio of 1:3 (same severity scores and colonisation index). Univariate and multiple regression analyses were performed. Of 130 severely burned patients with Candida spp colonisation and at least one episode of sepsis or septic shock, 14 were diagnosed with candidemia. In the candidemia group, patients had a median (IQR) total burns surface area (TBSA) of 57 (38-68)%, SAPSII of 43 (36-58) and ABSI of 11 (8-13). Multiple regression analysis showed that only duration of prior antibiotic therapy was independently associated with candidemia. ICU mortality was higher in the candidemia group (71% vs 35% [P = 0.02]). The log-rank test for 28-day mortality comparing patients with candidemia treated with an empirical strategy vs a curative strategy did not reach significance (P = 0.056). Burns patients having received recent antibiotherapy have a higher risk of candidemia. Antifungal strategies did not influence outcome in this series.

Sections du résumé

BACKGROUND BACKGROUND
Patients with extensive burns are at risk of developing candidemia.
OBJECTIVES OBJECTIVE
To identify potentially modifiable risk factors and outcomes of candidemia in critically ill burns patients.
PATIENTS AND METHODS METHODS
Retrospective matched cohort study including adult burns patients. Patients who developed candidemia were matched with burns patients with Candida spp colonisation and sepsis or septic shock without candidemia in a ratio of 1:3 (same severity scores and colonisation index). Univariate and multiple regression analyses were performed.
RESULTS RESULTS
Of 130 severely burned patients with Candida spp colonisation and at least one episode of sepsis or septic shock, 14 were diagnosed with candidemia. In the candidemia group, patients had a median (IQR) total burns surface area (TBSA) of 57 (38-68)%, SAPSII of 43 (36-58) and ABSI of 11 (8-13). Multiple regression analysis showed that only duration of prior antibiotic therapy was independently associated with candidemia. ICU mortality was higher in the candidemia group (71% vs 35% [P = 0.02]). The log-rank test for 28-day mortality comparing patients with candidemia treated with an empirical strategy vs a curative strategy did not reach significance (P = 0.056).
CONCLUSIONS CONCLUSIONS
Burns patients having received recent antibiotherapy have a higher risk of candidemia. Antifungal strategies did not influence outcome in this series.

Identifiants

pubmed: 30478963
doi: 10.1111/myc.12872
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

237-246

Subventions

Organisme : la fondation des gueules cassées

Informations de copyright

© 2018 Blackwell Verlag GmbH.

Auteurs

Emmanuel Dudoignon (E)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Alexandre Alanio (A)

Parasitology and Mycology laboratory, AP-HP, Hôpital Saint-Louis, Paris, France.
Université Paris Diderot, Paris, France.
Molecular mycology unit, Institut Pasteur, CNRS, UMR2000, Paris, France.

James Anstey (J)

Intensive Care Unit, Royal Melbourne Hospital, Parkville, Melbourne, Australia.

François Depret (F)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.
Université Paris Diderot, Paris, France.

Maxime Coutrot (M)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.
Université Paris Diderot, Paris, France.

Alexandre Fratani (A)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Marion Jully (M)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Alexandru Cupaciu (A)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Maïté Chaussard (M)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Haikel Oueslati (H)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Axelle Ferry (A)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Mourad Benyamina (M)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Christian de Tymowski (C)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

David Boccara (D)

Plastic Surgery and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Kevin Serror (K)

Plastic Surgery and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Marc Chaouat (M)

Plastic Surgery and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Maurice Mimoun (M)

Plastic Surgery and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Matthieu Lafaurie (M)

Department of Infectious Diseases, AP-HP, Hôpital Saint-Louis, Paris, France.

Blandine Denis (B)

Department of Infectious Diseases, AP-HP, Hôpital Saint-Louis, Paris, France.

Maud Gits-Muselli (M)

Parasitology and Mycology laboratory, AP-HP, Hôpital Saint-Louis, Paris, France.
Université Paris Diderot, Paris, France.
Molecular mycology unit, Institut Pasteur, CNRS, UMR2000, Paris, France.

Stephane Bretagne (S)

Parasitology and Mycology laboratory, AP-HP, Hôpital Saint-Louis, Paris, France.
Université Paris Diderot, Paris, France.
Molecular mycology unit, Institut Pasteur, CNRS, UMR2000, Paris, France.

Alexandre Mebazaa (A)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.
Université Paris Diderot, Paris, France.
Institut National de la Santé et de la Recherche Médicale (INSERM), UMR INSERM 942, Hôpital Lariboisière, F-CRIN INI-CRCT network, Univ Paris Diderot, Paris, France.

Matthieu Legrand (M)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.
Université Paris Diderot, Paris, France.
Institut National de la Santé et de la Recherche Médicale (INSERM), UMR INSERM 942, Hôpital Lariboisière, F-CRIN INI-CRCT network, Univ Paris Diderot, Paris, France.

Sabri Soussi (S)

Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, Hôpital Saint-Louis, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH